Carboplatin plus Paclitaxel

DRUG5 trials

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small Cell LungChemotherapy Induced NeutropeniaFallopian Tube CancerG-CSFOvarian CancerPeritoneal CancerPrimary Peritoneal Carcinoma

Phase 2

Personalised Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

RecruitingNCT07022535

The University of Hong KongFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer

Start: 2024-05-28End: 2025-12-31Target: 18Updated: 2025-07-02

Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer

RecruitingNCT07023484

The University of Hong KongFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma

Start: 2025-05-22End: 2028-12-31Target: 126Updated: 2025-07-02

Phase 3

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

TerminatedNCT00300885

BayerCarcinoma, Non-Small Cell Lung

Start: 2006-02-28End: 2009-02-28Updated: 2014-11-04

Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

Active, not recruitingNCT06726265

Immutep S.A.S.Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start: 2025-03-21End: 2029-09-01Target: 756Updated: 2026-03-18

Unknown Phase

A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.

Not yet recruitingNCT06649448

Shandong Cancer Hospital and InstituteChemotherapy Induced Neutropenia, G-CSF, Solid Tumor Cancer

Start: 2024-10-10End: 2026-05-31Target: 200Updated: 2024-10-18

Related Papers

A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer.

2025-12-12

TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.